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Malignant tumors are complex organs consisting of tumor cells and their microenvironment. Increasing evidence has shown 
that the tumor microenvironment is critical to the initiation and progression of tumors. Rational design of tumor therapies via 
targeting the tumor microenvironment to inhibit tumor growth is thus becoming a consensus strategy. Gd@C82(OH)22 nanopar-
ticles, as novel endohedral hydroxylated metallofullerenes, have been demonstrated to be a potent antitumor nanomedicine via 
targeting multiple factors in the tumor microenvironment. Gd@C82(OH)22 nanoparticles possess excellent biocompatibility and 
remarkable antineoplastic activity, as a result not of direct tumor cytotoxicity but of their diverse biological effects, including 
antioxidation, immune activation, angiogenesis inhibition, imprisoning cancer cells, and reversal of drug-resistance. In this ar-
ticle, we summarize the unique nanoscale physiochemical properties and the antineoplastic activities of Gd@C82(OH)22 nano-
particles, and focus on the mechanisms underlying their regulation of the tumor microenvironment.  
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Tumor therapy remains an important unresolved issue. The 
bottlenecks associated with traditional therapies have 
prompted the development of new treatments and a deeper 
understanding of the mechanisms of tumorigenesis and pro-
gression. Pathologically, cancer cells do not exist in isola-
tion, but create a complex context with their microenviron-
ment, which comprises proliferating tumor cells, tumor 
stroma, blood vessels, infiltrating inflammatory cells and a 
variety of associated stromal cells [1]. The tumor microen-
vironment operates complex mechanisms to maintain its 
dysregulated functions and to assist tumor cells to evade 
anticancer therapies. Ideally, to achieve maximal therapeu-
tic efficacy, antitumor agents should not only inhibit and 
destroy the tumor cells, but also normalize the tumor mi-
croenvironment. Therapeutic agents that target the tumor 
microenvironment thus represent an important new direc-
tion for the development of novel and effective antitumor 
therapies. Some drugs targeting the tumor microenviron-
ment, such as the angiogenesis inhibitor bevacizumab 
(Avastin), have already been approved by the US Food and 
Drug Administration for the treatment of several cancers 
[2,3]. 
Engineered nanoparticles, including a variety of carbon  
nanomaterials, are emerging as robust platforms with immense 
potential for effective cancer therapy [4]. Gd@C82(OH)22 is an 
endohedral metallofullerenol nanoparticle recently developed 
for biomedical applications, which has shown promising 
antineoplastic activity [5–9]. In contrast to other antitumor 
agents or nanomaterials, Gd@C82(OH)22 nanoparticles do 
not kill tumor cells directly, but rather inhibit tumor growth 
SPECIAL TOPIC 
 Li Y Y, et al.   Sci China Life Sci   October (2012) Vol.55 No.10 885 
and metastasis. Other studies have identified several underly-
ing mechanisms closely related to various components of the 
tumor microenvironment [8–13]. The current review exam-
ines the unique antineoplastic activity of Gd@C82(OH)22 na-
noparticles via regulation of the tumor microenvironment, 
as a novel antitumor strategy associated with the physio-
chemical properties of the nanomaterial.  
1  Characterization 
Gd@C82(OH)22 is an endohedral hydroxylated metallofuller-
ene (metallofullerenol) with a unique structure and surface 
features. It possesses a virus-like nanostructure, consisting 
of a magnetic metal core of a gadolinium (Gd) atom and a 
closed outer nanosheath of carbon atoms, which are further 
modified by about 22 outermost hydroxyl groups (Figure  
1) [9]. Several studies have found that the composition and 
numbers of the outer groups are largely responsible for the 
bioactive properties of fullerenol molecules [5,7,14–18]. 
The Gd@C82(OH)22 molecule is smaller than 2 nm, but 
Gd@C82(OH)22 tends to aggregate in aqueous solutions and 
forms dispersed Gd@C82(OH)22 nanoparticles with an av-
erage diameter of about 100 nm, which is a ubiquitous 
property identified in metallofullerenol studies [7]. 
Gd@C82(OH)22 nanoparticles exhibit a high degree of sta-
bility and good dispersion in physiological solutions [11]. 
The surface functionalization of the metallofullerene over-
comes the dissolvability limitation of conventional carbon 
nanomaterials, such as fullerenes and carbon tubes, and sig-
nificantly broadens the potential biomedical applications of 
Gd@C82(OH)22 nanoparticles. Further studies showed that 
Gd@C82(OH)22 nanoparticles maintained their optical 
transparency and remained within a constant size range over 
a period of 1 month in physiological media, and no signifi-
cant release of Gd3+ ions was detected by inductively cou-
pled plasma-mass spectrometry within 6 days, indicating the 
intrinsic stability of Gd@C82(OH)22 nanoparticles [11,13]. 
Some unique physicochemical properties of Gd@C82(OH)22 
nanoparticles have also been examined in subsequent stud-
ies [19–21].  
2  Biosafety 
Extensive studies have examined the biocompatibility and 
biosafety of Gd@C82(OH)22 nanoparticles and have found 
no discernible toxic effects either in vitro or in vivo. These 
observations may be attributable to the water-soluble mul-
ti-hydroxyl groups on the surface. Gd@C82(OH)22 nanopar-
ticles do not affect either the viability or proliferation of 
human primary immune cells (B cells, T cells or macro-
phages) or tumor cells (hepatoma cells or lung carcinoma 
cells), nor induce their apoptosis [7,11]. The nanoparticles 
could be delivered to most tissues and organs in mice 
through the blood circulation, but barely penetrated the 
blood-brain barrier [10]. Standard histopathological exami-
nations using hematoxylin-eosin (HE) staining revealed that 
Gd@C82(OH)22 nanoparticles induced no abnormal patho-
logical changes in the liver, spleen, kidney, heart, brain, or 
lung of treated mice, compared with untreated controls [7]. 
Comparison of the biodistributions of Gd@C82(OH)22 na-
noparticles and metallic Gd3+ suggest that the fullerene cage 
is not destroyed during metabolism in mice, and the internal 
Gd3+ is thus not liberated into the tissues [10]. In addition, 
Gd@C82(OH)22 nanoparticles caused no abnormal behavior, 
deaths or other systemic toxicities in tumor-bearing mice 
[10,11].  
In vivo toxicological studies are critical for the clinical 
development of all investigational nanomaterials. In addi-
tion to the traditional rodent animal models used in toxicity 
studies, the nematode Caenorhabditis elegans (C. elegans) 
has also been used to further evaluate the potential adverse 
in vivo effects of Gd@C82(OH)22 nanoparticles on organ-
isms under normal and stress conditions [22]. Treatment 
with Gd@C82(OH)22 nanoparticles up to 10 mg mL
1 within 
one generation (short-term) and six generations (long-term) 
resulted in no significant decreases in longevity or thermo-
tolerance in C. elegans. In addition, individual growth and 
development, feeding behavior and reproductive capability 
also remained relatively unchanged after exposure to the 
nanoparticles. Overall, these data demonstrate that 
Gd@C82(OH)22 nanoparticles are well tolerated by C. ele-
gans with no apparent toxic effects in either adult or young 
worms [22].  
All biosafety studies conducted so far have demonstrated 
that Gd@C82(OH)22 nanoparticles have a high safety profile, 
thus laying the foundations for the further development of 
biomedical applications. Furthermore, Gd@C82(OH)22 na-
noparticles have also recently been developed as a superior 
contrast agent for magnetic resonance imaging [5,6], ac-
companying their high efficiency for antitumor growth. 
 
 
Figure 1  Synthesis and structure of Gd@C82(OH)22. Reproduced with permission [9]. 
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3  Tumor suppression  
3.1  Antineoplastic activity of Gd@C82(OH)22 
Various lines of evidence have confirmed antineoplastic 
tumor-suppressing activity of Gd@C82(OH)22 nanoparticles 
and identified their molecular mechanisms since the nano-
particles were reported to prevent tumor proliferation in a 
rodent hepatocellular carcinoma model in 2005 [7]. The 
nanoparticles, at a dose as low as 107 mol kg1, inhibit 
hepatocellular damage in association with about 60% inhi-
bition of tumor growth [7]. Although the molar dosage of 
Gd@C82(OH)22 nanoparticles was approximately 1/500 that 
of the antineoplastic agent cyclophosphamide, their effi-
ciency was much higher under the same experimental con-
ditions, and no observable damage to any important organs 
was reported [7]. Furthermore, Gd@C82(OH)22 nanoparti-
cles significantly inhibited lung tumor growth, with average 
inhibition rates for nanoparticles administered at 107 mol 
kg1 and 5×107 mol kg1 40.2% and 45.3%, respectively 
[11]. Gd@C82(OH)22 nanoparticles could also efficiently 
prohibit liver, kidney and lung damage in tumor-bearing 
mice, and the organ functions were significantly improved 
[7,10,23]. The efficacy of treatment with Gd@C82(OH)22 
nanoparticles in breast-tumor-bearing nude mice was com-
parable to the commonly used clinical anticancer drug 
paclitaxel, with no detectable side effects [9]. Moreover, 
Gd@C82(OH)22 nanoparticles could reactivate defective 
endocytosis of cisplatin in cisplatin-resistant (CP-r) cells, 
and tumor resistance to cisplatin was overcome by treatment 
with a combination of Gd@C82(OH)22 nanoparticles and 
cisplatin, both in vitro and in vivo [24].  
3.2  Antineoplastic mechanisms of Gd@C82(OH)22  
The high antitumor efficiency of Gd@C82(OH)22 nanoparti-
cles is not the result of traditional cytotoxic effects, but ra-
ther their direct regulation of the tumor microenvironment. 
The nanoparticles do not kill tumor cells directly, and less 
than 0.05% of the exposed dose of Gd@C82(OH)22 nanopar-
ticles was distributed in the tumor tissues in tumor-bearing 
mice [7,11]. 
3.2.1  Reactive oxygen species-scavenging/antioxidative 
function 
Oxidative stress is a response to the abnormal metabolism 
of reactive oxygen species (ROS) in aerobic organisms, and 
is considered an important mechanism in carcinogenesis. 
ROS can react with most biological macromolecules to 
cause oxidative damage and participate in building the in-
tricate tumor microenvironment. Regulating oxidative stress 
is thus an important part of regulating the tumor microenvi-
ronment, and Gd@C82(OH)22 nanoparticles can play an im-
portant role in regulating the oxidative defense system in 
vivo. These nanoparticles have been shown to inhibit the 
proliferation of solid tumors and decrease the activities of 
hepatic superoxide dismutase, glutathione peroxidase, glu-
tathione S-transferase and catalase, as well as the levels of 
reduced glutathione, protein-bound thiols and malondialde-
hyde, which are responsible for catalyzing the production of 
ROS in vivo [10]. All major physiologically relevant ROS, 
including superoxide radical anion, hydroxyl radical and 
singlet oxygen, can also be scavenged directly by 
Gd@C82(OH)22 nanoparticles [8,23]. Inhibition of lipid pe-
roxidation and mitochondrial damage are also observed 
after treatment with Gd@C82(OH)22 nanoparticles both in 
vitro and in vivo [23]. These results indicate that 
Gd@C82(OH)22 nanoparticles can exert antitumor activity 
via regulating oxidative stress in the tumor microenviron-
ment.  
3.2.2  Cellular immunity activation  
Upregulation of the inflammatory immune responses is a 
classical strategy for rapid tumor proliferation and metasta-
sis. Gd@C82(OH)22 nanoparticles could trigger anti-infla-       
mmatory immune responses by activating lymphocytes and 
macrophages both in vitro and in vivo. Gd@C82(OH)22 na-
noparticles showed a strong capacity for improving immun-
ity and interfering with hepatocellular carcinoma invasion 
in normal muscle cells and tumor-bearing mice [7]. En-
hanced immunity can induce various effects such as lym-
phocyte proliferation and neutrophil migration into tumor 
tissues, and lymphocyte hyperplasia (lymphopoiesis), and 
aggregated follicles clearly appeared around the transplant-
ed tumor tissues in Gd@C82(OH)22 nanoparticle-treated 
animals. Gd@C82(OH)22 nanoparticles can also inhibit the 
growth of lung carcinomas through specific immunomodu-
latory effects on T cells and macrophages, including polar-
izing the cytokine balance towards Th1 cytokines, decreas-
ing the production of Th2 cytokines, and increasing the 
production of Th1 cytokines [11]. The nanoparticles stimu-
lated immune cells to release tumor necrosis factor-α, which 
plays an important role in cellular immune processes. Den-
dritic cells (DCs) also play a pivotal role in host immune 
defense, including inhibiting tumorigenesis. Gd@C82(OH)22 
nanoparticles are a potent activator of DCs towards the Th1 
immune response. They could induce the phenotypic matu-
ration of DCs by stimulating their production of cytokines, 
including interleukin-12p70, upregulating DC co-stimula-      
tory and MHC molecules, and switching DCs from a CCL5-      
responsive to a CCL19-responsive phenotype [12]. Overall, 
the results of these experiments suggest that Gd@C82(OH)22 
nanoparticles can effectively regulate the tumor microenvi-
ronment by regulating the host immune system to scavenge 
tumor cells (Figure 2) [11].  
3.2.3  Angiogenesis inhibition 
Tumor blood vessels are essential for the growth and sur-
vival of solid tumors. They also support the metastasis of 
tumor cells in the tumor microenvironment. Angiogenesis  
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Figure 2  Possible immune-related mechanisms of Gd@C82(OH)22 nanoparticles in inhibiting tumor growth. Reproduced with permission [11]. 
inhibition is emerging as an important strategy in the de-
velopment of antitumor therapies, in addition to therapies 
aimed at directly killing or removing tumor cells. A variety 
of angiogenic inhibitors have been approved or are currently 
under investigation in clinical studies. However, the effi-
ciencies of most small molecule and peptide inhibitors and 
antibody-based regulators are reduced in clinical studies, 
because their narrow inhibition spectra increase the risk of 
drug-resistance and side effects associated with a lack of 
specificity.  
Gd@C82(OH)22 nanoparticles represent a new ‘particu-
late form’ of angiogenesis inhibitor, with more favorable 
features than the traditional ‘molecular form’ inhibitors. 
Gd@C82(OH)22 nanoparticles have a wide inhibition spec-
trum of more than 10 angiogenic factors [9]. At the mRNA 
level, the group of genes encoding fibroblast growth factor 
(FGF)1, FGF6, FGF receptor 3; chemokine (CXC motif) 
ligand (CXCL) 1, CXCL2, CXCL5, matrix metalloprotein-
ase (MMP) 19, MMP2, MMP9, laminin subunit α-5, and 
transforming growth factor (TGF) b1 and TGFb2 were sig-
nificantly and simultaneously downregulated by treatment 
with Gd@C82(OH)22 nanoparticles [9]. These promising 
observations have been further confirmed at the protein lev-
el [9]. The migration of human microvascular endothelial 
cells was suppressed by more than 80% in vitro, and the mi-
crovessel density in tumors was decreased by more than 40% 
after nanoparticle treatment [9]. Furthermore, Gd@C82(OH)22 
nanoparticles largely reduced tumor blood perfusion and 
efficiently lowered the speed of blood flow to tumor tissues 
by about 40% [9]. The results of in vivo experiments 
showed that Gd@C82(OH)22 nanoparticles potently inhibited 
tumor growth, with a tumor-inhibition rate higher than the 
clinical breast-cancer-specific chemotherapeutic agent 
paclitaxel, at a dosage of Gd@C82(OH)22 nanoparticles 
one-third the dose of paclitaxel [9]. At the same time, 
Gd@C82(OH)22 nanoparticles did not interfere with normal 
blood vessels, and no changes in the morphology of capil-
lary vessels in normal tissue were seen, including no pro-
nounced abnormalities such as gaps, disfigurements or 
breaches in the cell layer in blood vessels. These findings con-
firm the angiogenesis-inhibitory activity of Gd@C82(OH)22 
nanoparticles in the tumor microenvironment (Figure 3) [9]. 
3.2.4  Imprisoning rather than poisoning of cancer cells 
Tumor metastasis is a major contributor to over 90% of 
cancer-associated deaths. MMPs are critical regulators se-
creted mainly by tumor-associated macrophages in the tu-
mor microenvironment. MMPs degrade extracellular matrix 
proteins and ease tumor invasiveness at the initial stage of 
tumor metastasis. Downregulation of MMP expression in 
the tumor microenvironment is known to be a major con-
tributory factor in the decreased metastatic potential of tu- 
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Figure 3  In vivo anti-angiogenic effects of Gd@C82(OH)22 nanoparticles 
in mice. A, Morphology of tumor tissue treated with Gd@C82(OH)22 nano-
particles. B, Tumor tissues stained for CD31 immunohistochemistry  
showing reduced blood vessel density. Reproduced with permission [9]. 
mors.  
High-throughput gene-array analysis studies have re-
vealed that members of the MMP family are strongly inhib-
ited in response to Gd@C82(OH)22 nanoparticle treatment 
[9]. Further studies revealed that Gd@C82(OH)22 nanoparti-
cles potently inhibited the production of MMPs at both the 
mRNA and protein levels in an MDA-MB-231 cancer 
cell-macrophage co-culture system, and cancer cell invasion 
was accordingly restrained in vitro [13]. In a tissue-invasion 
model, Gd@C82(OH)22 nanoparticles significantly sup-
pressed tumor metastasis at the ectopic site, along with de-
creases in MMP-9 and MMP-2 expression of more than 90% 
and 60%, respectively. Interestingly, histological examination 
by Van Gieson staining of primary subcutaneous tumors de-
rived from MDA-MB-231 cells demonstrated a thick fibrous 
layer on the tumor surface in Gd@C82(OH)22 nanoparti-
cle-treated mice, but not in saline-treated mice [13]. In an- 
other breast-cancer model derived from MCF-7 cells, the 
fibrous layer surrounding the surface of the tumor was 
about 578 μm thick in the nanoparticle-groups, compared 
with about 32 μm in the saline-treated group. At the same 
time, no remarkable deposition of fibrous tissue was ob-
served in any major organs other than the tumors [13]. In a 
bloodstream-transfer model in which MDA-MB-231 cancer 
cells were injected directly into the tail vein of nude mice, 
intraperitoneal Gd@C82(OH)22 nanoparticles injected daily 
for 6 weeks significantly inhibited the establishment of tu-
mor foci in the lung [13]. Tumors were detected in the lungs 
at about 21 days after cancer cell injection in the saline 
group, but no cancers were detected in mice treated with 
Gd@C82(OH)22 nanoparticles until day 42. Histological ex-
amination revealed the presence of numerous tumor foci in 
saline-treated controls, and minimal signs of tumors in the 
nanoparticle-treated group, highlighting the efficacy of 
Gd@C82(OH)22 nanoparticles. These findings suggest that 
Gd@C82(OH)22 nanoparticles operate via a new antitumor 
mechanism. The formation of a thick fibrous cage may act as 
a ‘prison’, confining invasive tumor cells to their primary site 
and thus effectively inhibiting the tumor via imprisoning, 
rather than poisoning the tumor cells (Figure 4) [13]. 
3.2.5  Restoring defective endocytosis 
Chemotherapy remains a mainstream treatment in clinical 
tumor therapy, but its high toxicity and the easy develop-
ment of drug-resistance greatly impede its applications. The 
loss of sensitivity of cells to chemotherapeutic drugs is a 
result of interactions between tumor cells and their micro-
environment. Cisplatin is a commonly used chemotherapeu-
tic agent for a number of epithelial malignancies; however,  
 
 
Figure 4  Schematic representation of possible anti-metastatic mechanism of Gd@C82(OH)22 nanoparticles (NPs) mainly via a MMP-inhibition process. 
The thick fibrous cage may act as a ‘prison’ to confine invasive cancer cells within the primary site. Reproduced with permission [13]. 
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the appearance of CP-r human prostate cancer cells seri-
ously reduces its clinical efficacy. CP-r cells show defective 
endocytosis, which may lead to diminished accumulation of 
cisplatin and thus confer resistance. Gd@C82(OH)22 nano-
particles could restore transferrin-mediated endocytosis, 
thus circumventing the acquired resistance of CP-r cells by 
enhancing uptake of cisplatin (Figure 5) [24]. Exposure of 
CP-r cells to cisplatin in the presence of Gd@C82(OH)22 
nanoparticles not only decreased the numbers of surviving 
CP-r cells, but also inhibited growth of CP-r tumors in 
athymic nude mice [24]. Measurement of cellular viability 
and cytotoxicity indicated that the nanoparticles were non-
toxic to cancer cells in vitro, yet could successfully inhibit 
tumor growth in conjunction with cisplatin in CP-r tumors 
in vivo (Figure 5) [24]. 
4  Prospects 
Recent advances in cancer nanotechnology along with its 
wide application in biomedicine offer new potential cancer  
 
 
Figure 5  Schematic illustration of mechanism whereby Gd@C82(OH)22 
nanoparticles could increase CP-r cell sensitivity to cisplatin. Reproduced  
with permission [24]. 
therapeutic strategies. Gd@C82(OH)22 nanoparticles, among 
the many biomedical nanomaterials with distinct antitumor 
properties, hold great promise associated with their novel 
antitumor activities via regulation of the tumor microenvi-
ronment. Growing awareness of the importance and com-
plexity of the tumor microenvironment means that rational 
drug combinations targeting the whole ‘tumor organ’, name-
ly both tumor cells and their microenvironment, are emerging 
as the mainstream of cancer therapy. Gd@C82(OH)22 nano-
particles, as an excellent example of ‘particulate medicine’, 
represent a promising new opportunity for relieving the 
suffering of cancer patients in the near future.  
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